OpenPlacement and Ensocare Partner to Provide Patients Leaving Hospital with More Insight About Post-Acute Care Providers

(Omaha, NE) Ensocare, a leading provider of technology-enabled care coordination solutions, announced today that it has partnered with OpenPlacement to provide hospital patients nationwide the ability to use consumer tablet technology at their bedside to connect with post-acute care providers prior to being discharged.

OpenPlacement already provides patients and families with an online search and booking-type of solution and real-time access to care options. According to Wayne Sensor, CEO of Ensocare, combining OpenPlacement’s patient engagement interface with Ensocare’s network and technology solution is a match that stands to benefit a significant number of the tens of millions of patients who are discharged from hospitals across the country each year.

“Ensocare’s solutions are geared toward increasing efficiency and coordination of care for patients both before and after discharge,” he said. “By partnering with OpenPlacement, we’re able to take what Ensocare does extremely well and extend the benefits even further to patients and their families who are seeking quality senior care.”

According to Sensor, hospital patients and their families are often faced with having to select a nursing home or post-acute care facility quickly, during an already stressful time, with very little information. Ensocare’s unique technology solution, which is used by hospital discharge planners and case managers, quickly matches the patient’s clinical needs with the capabilities of post-acute care facilities nationwide. Ensocare’s leading-edge technology is strengthened by its exclusive, national, no-cost network of post-acute care facilities.

This “short list” of facilities with the right clinical services can then be reviewed by patients and their family members at the bedside using convenient touchscreen tablets. From there, patients can obtain facility profiles, photos, videos, reviews from current and past patients and facility comparison information. They can also message facilities directly from the tablet.

Lu Castillo, President of Ensocare, said the partnership strengthens both companies’ solution and its position in the market. “Our relationship with OpenPlacement will help engage patients and their families in their own care transition process,” he said. “This benefits our provider customers, our post-acute facility network members and, most importantly, patients and families.”

Starting in early 2016, Ensocare will make OpenPlacement accessible to current customers, and also communicate OpenPlacement as an option to the care facilities that are part of its unique post-acute network.

“Together, Ensocare and OpenPlacement are changing the way patients are discharged from the hospital,” said Castillo.

About Ensocare

Ensocare provides care coordination solutions, risk stratification and readmissions analytics to help manage patient care transitions, shorten hospital length of stay, reduce readmissions and improve patient outcomesEnsocare’s advanced technology unites patients, families and health-care organizations to ensure that patients get the right care at the right time after discharge.

About OpenPlacement

OpenPlacement provides patients, families and care coordinators real-time information and tools so they can qualify post-acute and long-term care providers. Through its website and mobile application, OpenPlacement helps patients and families select the right provider for their post-acute needs to make care transitions easy.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.